×

MediWound's NexoBrid(R) Highlighted at the 16th European Burns Association Congress

YAVNE, Israel, Sept. 10, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that an industrial workshop, satellite symposium and multiple presentations at the upcoming 16th European Burns Association (EBA) Congress will highlight the positive clinical outcomes resulting from the growing use of NexoBrid® throughout Europe as an effective enzymatic debridement for severe burns. The Congress will take place on September 16-19, 2015 at the Convention Center in Hanover, Germany.

In addition to hosting an Exhibit Booth on the Exposition Floor throughout the duration of the Congress, MediWound is sponsoring a clinical workshop titled "NexoBrid: A Practical Approach," which will be chaired by Bernd Hartmann, MD, Head of the Burn Center/Department for Plastic Surgery, Berlin, Germany. During the workshop, to be held September 16th from 4:00 p.m. to 5:30 p.m., experienced burn specialists will share their knowledge and technical tips for successful treatment with NexoBrid, and will assist participants with integrating NexoBrid into their daily practices.

Also, Professor Hans-Oliver Rennekampff, President of the German Burn Association, RWTH University, Aachen, Germany, will chair a symposium titled, "NexoBrid: From Unmet Need to Common Practice," on September 18th from 12:30 p.m. to 2:00 p.m. The symposium will feature a variety of topics, including:

  • "The Unmet Need In Burn Care" led by Juan P. Barret, MD ,Spain
  • "NexoBrid vs. the Unmet Need" led by Fredrik Huss, MD, Sweden
  • "The Paradigm Shift" led by Stan Monstrey, MD, Belgium
  • "Common Practice – Mastering the Learning Curve" led by Alexandra Schulz, MD, Germany
  • MediWound's commitment to burn and wound care
  • Summary and Question and Answer session moderated by Dr. Rennekampff

"We are looking forward to the EBA, which is expected to be the most comprehensive burn conference in Europe in the coming two years. The volume and variety of presentations by leading burn clinicians from across Europe highlighting the clinical and pharmacoeconomic merits of NexoBrid for the treatment of severe burns are very gratifying," said Gal Cohen, President and Chief Executive Officer of MediWound. "The wealth of data being presented underscores the growing usage of NexoBrid in the treatment of severe burns and bodes well for its potential to become the standard-of-care."

In addition to the clinical workshop and symposium, NexoBrid will be highlighted in 26 presentations. The abstracts for the presentations can be accessed at http://www.eba2015.de/programme/scientific-programme/. The following presentations will be delivered during the EBA meeting:

Title: "Summary of pediatric clinical experience with NexoBrid"
Speakers: Yaron Shoham, MD, Plastic and Reconstructive Surgery Department, Soroka University Medical Center, Beer Sheva, Israel
Session: Pediatric Burn II
Title: "Enzymatic debridement"
Speakers: Paul Christian Fuchs, MD, Fellow of the European Board of Plastic Reconstructive and Aesthetic Surgery, Kliniken der Stadt Koln, Koln, Germany
Session: DGV Session – Debridement in burns
Title: "Enzymatic surgery based minimal invasive modality for burn care"
Speakers: Prof. Lior Rosenberg, MD, Head of the Department of Plastic Surgery, Soroka University Medical Center, Beer Sheva, Israel
Session: Non-Surgical Treatment I
Title: "A NexoBrid comprehensive approach to pediatric hands and feet full thickness burns"
Speakers: Yaron Shoham, MD, Plastic and Reconstructive Surgery Department, Soroka University Medical Center, Beer Sheva, Israel
Session: Pediatric Burn III
Title: "First experience with the use of NexoBrid in deep burns of the scalp"
Speakers: Antonio Di Lonardo, MD, Head of OUC Burn Center, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Session: Burn in Elderly
Title: "Enzymatic Burn Debridement with NexoBrid®: Application and wound evaluation presenting different problems"
Speakers: Frank Sander, MD, Specialist in Plastic and Aesthetic Surgery, Trauma Hospital Berlin, Berlin, Germany
Session: Non-Surgical Treatment I
Title: "Selective enzymatic debridement of deep partial and full thickness burn wounds with a bromelain-based topical debriding agent – first experiences"
Speakers: Tobias Jaehn, MD, Clinic for Plastic, Reconstructive and Hand Surgery, Center for Severe Burn Injuries, University Hospital of the Paracelsus Medical University, Nurnberg, Germany
Session: DGV Session Innovations in burns – the German contribution
Title: "Challenges met during the implementation of a new treatment at the Helsinki Burn Centre in Finland"
Speakers: Charlene Pivat, RN, Burn Centre, Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Session: Data Collection and Studies/Burn Registries II
Title: "Early enzymatic debridement of deep dermal burns – results in hands and preliminary results in face and lower extremity"
Speakers: Alexandra Schulz, MD, Department of Plastic Surgery, Hand Surgery, Burn Center, University of Witten/Herdecke, Cologne-Merheim Medical Center, Cologne, Germany
Title: "Saving the dermis: Initial experience with minimally invasive enzymatic debridement in the Slovak Republic"
Speakers: Peter Lengyel, MD, PhD, Head of the Department of Burns and Reconstructive Surgery, Hospital Kosice-Saca, Kosice-Saca, Slovakia
Session: Non-Surgical Treatment II
Title: "Including enzymatic debridement in the standard of care: our protocol"
Speakers: Jose Ramon Martinez-Mendez, MD, Plastic Surgery, Hospital Universitario La Paz, Madrid, Spain
Session: Acute Care
Title: "The safe use of NexoBrid: Results of a Safety Study"
Speakers: Prof. Lars-Peter Kamolz, MD, Head of Plastic Surgery, Medical University of Graz, Graz, Austria
Session: Burn research
Title: "Pitfall when using enzymatic debridement by bromelain. Lessons learnt after 2 cases."
Speakers: Nadine Hans, MD, Orthopedic Surgery, Burns Treatment Center, Grand Hospital de Charleroi, Charleroi, Belgium
Session: Non-surgical treatment
Title: "Early Enzymatic debridement of deep dermal burns: First results of using our pain and care protocol for the application of a bromelain based enzymatic debridement"
Speakers: Patrick Persoon, RN, Brussels, Belgium
Session: Non-surgical treatment
Title: "Burn depth Assessment: LDI versus NEXOBRID"
Speakers: Henk Hoeksema, RN, Plastic Surgery, Universitair Ziekenhuis Ghent, Gent, Belgium
Session: Non-surgical treatment
Title: "Health economic considerations to a new debriding agent for deep partial and full thickness burns"
Speakers: Willi Schnorpfeil, MD, Solutions for Health Consulting, Eschborn, Germany
Session: Non-surgical treatment
Title: "Budget impact analysis of NexoBrid in the perspective of Italian hospitals"
Speakers: Mario Cherubino, MD, Plastic Surgery, Universita degli Studi dell'Insubria, Varese, Italy
Session: Financing/Guidelines/Structures
Title: "Initial experience with NexoBrid enzymatic debridement of deeply burned hands"
Speakers: Edward Caleffi, MD, Director of Plastic Surgery and Burns Centre, University Hospital of Parma, Parma, Italy
Session: Non-surgical treatment
Title: "Healing the post NexoBrid debridement wound bed"
Speakers: Yaron Shoham, MD, Plastic and Reconstructive Surgery Department, Soroka University Medical Center, Beer Sheva, Israel
Session: Primary acute care
Title: "Cosmetic and Functional Advantage in the Use of NexoBrid for Problematic Burnt Areas"
Speakers: Simon PIlson, MD, Department of Plastic Surgery, Rambam Health Care Campus, Haifa, Israel
Session: Primary acute care
Title: "The role of an effective, fast & specific enzymatic debriding agent (NexoBrid) in the care of mass burns in a disaster scenario"
Speakers: Prof. Lior Rosenberg, MD, Head of the Department of Plastic Surgery, Soroka University Medical Center, Beer Sheva, Israel
Session: Primary acute care
Title: "Implementation of a new technology in the burn unit – how to convert the difficulty into a challenge"
Speakers: Sima Ben Shitrit, RN, Head Nurse, Department of Plastic Reconstructive Surgery, Rambam Health Care Campus, Haifa, Israel
Session: Primary acute care
Title: "Treatment of partial and full thickness burns of two hands by enzymatic debridement with NexoBrid®: a case-report"
Speakers: Kelly Kwa, MD, Leiden University Medical Center, Leiden, Netherlands
Session: Primary acute care
Title: "Full thickness constricting burn of the breast area successfully treated with NexoBrid enzymatic debridement"
Speakers: Karin Engblom, RN, Uppsala Clinical Research Center, Uppsala, Sweden
Session: Primary acute care
Title: "A Swedish experience of introducing NexoBrid to the clinic"
Speakers: Fredrik Huss, MD, Consultant, Department of Surgical Sciences, Surgery, Burn Centre, Uppsala, Sweden
Session: Non-surgical treatment
Title: "Acute burn depth diagnosis and debrided wound coverage/closure options following rapid minimally invasive enzymatic debridement"
Speakers: Jan Koller, MD, PhD, Associate Professor of Surgery, Centre for Burns and Reconstructive Surgery, Ruzinov University Hospital, Bratislava, Slovakia
Session: Primary acute care

About the European Burns Association

The European Burns Association (EBA) is a non-profit organization dedicated to the promotion of burn prevention, the study of the prevention of burn injury and all aspects of burn treatment. It also serves as a resource to facilitate communication and collaboration between burn care specialists. An exchange of information between the various burn centers in Europe will help the EBA to promote its goals. The purpose of the Congress is to bring medical specialists, researchers, paramedics, nurses and other workers in contact to discuss aspects of burn treatment and research.

About NexoBrid

NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid was granted marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in Europe and Israel. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or "debridement" is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard-of-care (SOC), burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli Ministry of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials and the regulatory authorizations. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the FDA or the EMA regulatory approval process or additional competition in the market. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACT: Sharon Malka Chief Financial & Operation Officer MediWound Ltd. ir@mediwound.co.il Anne Marie Fields Senior Vice President LHA 212-838-3777 afields@lhai.com

Source:MediWound